Johnson Financial Group Inc (Wisconsin)’s Alexion Pharmaceuticals ALXN Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-197	Closed	-$19K	–	561
2018 Q4	$19K	Sell	197 -4,785	-96%	-$566K	﹤0.01%	393
2018 Q3	$693K	Buy	4,982 +141	+3%	+$17.7K	0.07%	149
2018 Q2	$601K	Buy	4,841 +121	+3%	+$14.1K	0.07%	154
2018 Q1	$527K	Sell	4,720 -400	-8%	-$47.8K	0.06%	161
2017 Q4	$612K	Buy	5,120 +938	+22%	+$114K	0.08%	155
2017 Q3	$587K	Buy	4,182 +4,152	+13,840%	+$564K	0.08%	149
2017 Q2	$4K	Buy	+30	New	+$3.49K	﹤0.01%	518
2016 Q3	–	Sell	-801	Closed	-$94K	–	753
2016 Q2	$94K	Buy	801 +710	+780%	+$101K	0.01%	368
2016 Q1	$13K	Hold	91	–	–	﹤0.01%	583
2015 Q4	$17K	Buy	91 +27	+42%	+$4.72K	﹤0.01%	568
2015 Q3	$10K	Hold	64	–	–	﹤0.01%	657
2015 Q2	$12K	Hold	64	–	–	﹤0.01%	668
2015 Q1	$11K	Hold	64	–	–	﹤0.01%	680
2014 Q4	$12K	Hold	64	–	–	﹤0.01%	634
2014 Q3	$11K	Hold	64	–	–	﹤0.01%	610
2014 Q2	$10K	Hold	64	–	–	﹤0.01%	601
2014 Q1	$10K	Hold	64	–	–	﹤0.01%	591
2013 Q4	$9K	Hold	64	–	–	﹤0.01%	590
2013 Q3	$7K	Hold	64	–	–	﹤0.01%	589
2013 Q2	$6K	Buy	+64	New	+$6.17K	﹤0.01%	607

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s ALXN Position: Q1 2019 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 197 shares — an estimated $19K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in ALXN in Q2 2013 and held it in 20 quarters. The position peaked at $693K in Q3 2018. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Johnson Financial Group Inc (Wisconsin) reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Johnson Financial Group Inc (Wisconsin) sold 197 Alexion Pharmaceuticals shares in Q1 2019, an estimated $19K.
Johnson Financial Group Inc (Wisconsin) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 20 quarters.
Johnson Financial Group Inc (Wisconsin)'s Alexion Pharmaceuticals position peaked at $693K in Q3 2018.
612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2019, filed 13 May 2019.